Strategic collaboration yields unprecedented electronic filing by Maxim Pharmaceuticals

PAREXEL International Corporation (Nasdaq: PRXL), one of the world’s largest biopharmaceutical outsourcing companies, today announced the addition of Matthew J. Thatcher, MD, as a Principal Consultant in the Worldwide Regulatory Affairs group.

PAREXEL International Corporation (Nasdaq: PRXL) today announced that it has been selected for inclusion in the NASDAQ Biotechnology Index (NASDAQ: NBI) effective with the opening of the stock market on Monday, November 24, 2003.

Advanced imaging solutions offered for clinical trials

Earnings per share increased by 38.5%

PAREXEL International Corporation (Nasdaq: PRXL) announced the appointment of Ms. Susan Alexander to the position of Senior Vice President and General Counsel.

PAREXEL International Corporation (Nasdaq: PRXL) will release First Quarter FY 2004 financial results on Tuesday, October 21, 2003 before the opening of trading.

KMI/PAREXEL, an operating unit of PAREXEL International Corporation, (Nasdaq: PRXL), is pleased to announce formation of a strategic alliance with Learnwright, Inc., an e-learning solutions provider headquartered in Rockville, Maryland.

PAREXEL International Corporation (Nasdaq: PRXL) announced today it would be presenting at the Thomas Weisel Partners Healthcare Tailwinds 2003 Conference at the Four Seasons Hotel in Boston, MA.

PAREXEL International Corporation (Nasdaq: PRXL), a leading biopharmaceutical outsourcing provider, today announced that FARMOVS-PAREXEL, located in Bloemfontein, South Africa, has formed a strategic alliance with the Academic Group Practice (AGP) of the Faculty of Health Sciences, University of the Free State, also located in Bloemfontein.

Fiscal year revenue grows 15%

PAREXEL International Corporation (Nasdaq: PRXL), today announced that Alberto Grignolo, PhD, has been named President-elect of the Drug Information Association (DIA) Board of Directors as a result of a vote of the DIA membership.

PAREXEL International Corporation (Nasdaq: PRXL) will release Fourth Quarter and Fiscal 2003 financial results on Thursday, August 7, 2003 before the opening of trading.

First-in-Man and Proof of Concept facility expands to 23,000 square feet

Targets trial market with continuous cardiopulmonary monitoring tool

Barnett International, an operating unit of PAREXEL International Corporation (Nasdaq: PRXL), is pleased to announce the release of Good Clinical Practic

Revenue grows by 18.1% year-over-year
Operating margin improves by 2.2 percentage points year-over-year to 6.3%

Strengthens Worldwide Clinical Research Services Capabilities

PAREXEL International Corporation (Nasdaq: PRXL) will update forward-looking earnings expectations for the third quarter of Fiscal Year 2003 and for Fiscal 2003 in its entirety at its Investor conference being held tomorrow in New York City.

PAREXEL International Corporation (Nasdaq: PRXL) today announced that its Board of Directors has adopted a Shareholder Rights Plan.

PAREXEL International Corporation (Nasdaq: PRXL), one of the largest contract pharmaceutical outsourcing organizations in the world, announced today that it will broadcast its Investor Day live over the Internet on Wednesday, April 9th from 8:30 a.m. to 12:30 p.m. ET.

PAREXEL International Corporation (Nasdaq: PRXL) will release Third Quarter FY 2003 financial results on Wednesday, April 23, 2003 before the opening of trading.

PAREXEL International Corporation (Nasdaq: PRXL) announced today it will be presenting at the SG Cowen 23rd Annual Healthcare Conference at the Boston Marriott Copley Place Hotel in Boston, MA.

Barnett International, a division of a wholly owned subsidiary of PAREXEL International Corporation (NASDAQ: PRXL), announced the release of HIPAA and Human Subjects Research

PAREXEL International Corporation (Nasdaq: PRXL) announced today it will be presenting at the UBS Warburg Global Healthcare Services Conference at The Plaza Hotel in New York City.

Net new business increases by 29% from June 2002
Company’s gross margin improves 240 basis points to 33.4%

Adds market-leading electronic clinical trial management capabilities to Perceptive Informatics, Inc. portfolio

Barnett International, a subsidiary of PAREXEL International Corporation (NASDAQ: PRXL), has successfully tested an innovative graphical display of adverse drug reaction (ADR) data with the World Health Organization’s (WHO) Collaborating Centre for International Drug Monitoring in Uppsala, Sweden.

PAREXEL International Corporation (Nasdaq: PRXL) will release Second Quarter FY 2003 financial results on Wednesday, January 22, 2003 before the opening of trading.

PAREXEL International Corporation (Nasdaq: PRXL), a leading, worldwide biopharmaceutical outsourcing company, and Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic testing, information and services, announced a collaboration in which PAREXEL and Quest Diagnostics Clinical Trials will co-market their services to pharmaceutical and biotechnology companies worldwide.